Otros idiomas Candel Therapeutics, Inc.

Acciones

CADL

US1374041093

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
9,02 ^USD	+7,00 %		+41,16 %	+513,61 %

11/04	Actualización del sector: Los valores del sector sanitario bajan el jueves por la tarde	MT
11/04	Las acciones de Candel Therapeutics suben tras la designación de medicamento huérfano por la FDA para un potencial fármaco contra el cáncer de páncreas	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting	25/04
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech	16/04
Sector Update: Health Care Stocks Decline Thursday Afternoon	11/04
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	11/04
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation	11/04
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer	11/04
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	09/04
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell	05/04
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday	05/04
Top Premarket Gainers	05/04
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial	05/04
Top Midday Gainers	04/04
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	04/04
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	28/03
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	28/03
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights	28/03
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Candel Therapeutics, Inc.

Acciones

CADL

US1374041093

Otros idiomas

Filtros